Xiaojie Bian, Hao Zeng, Hongqian Guo, Nianzeng Xing, Yong Yang, Boxin Xue, Xiaoping Zhang, Wenjun Xiao, Junhui Jiang, Ting Sun, Wei Chen, Yong Wang, Ben Wan, Dalin He, Qi Zhang, Hong Luo, Xiaolin Wang, Jianming Guo, Huadong Zhao, Dingwei Ye. "Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.5047